For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

Ahead of Apple's 'Glowtime' event on Sept. 9, we're seeing iPhone 16 rumors about a tetraprism lens, A18 chips, an iPhone 16 ...

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of lung cancer cases. The treatment plan and goal of treatment depend on the stage of your NSCLC ...

The following is a summary of “Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 ...

The partnership is slated to add work at Kincell's site in Gainesville, Florida, the company said in a Sept. 16 press release ...

Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival ...

AstraZeneca Plc (NASDAQ:AZN) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) ...

A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival ...

Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) continu ...

ORRs of 54.8% and 50.0% achieved in locally advanced and metastatic cSCC, with median follow-up durations of 24.1 and 29.3 months, respectively. Results demonstrate a deepening of response over time, ...